Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200-Day Moving Average of $1.07

Regulus Therapeutics Inc (NASDAQ:RGLS) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.07 and traded as high as $0.57. Regulus Therapeutics shares last traded at $0.57, with a volume of 100 shares traded.

Several research analysts have commented on the stock. ValuEngine upgraded shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research report on Friday, August 16th. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, August 13th. Finally, Wedbush restated a “hold” rating and issued a $1.00 target price on shares of Regulus Therapeutics in a research report on Thursday, May 16th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Regulus Therapeutics currently has an average rating of “Hold” and a consensus target price of $1.08.

The stock has a market cap of $11.96 million, a P/E ratio of -0.11 and a beta of 1.90. The firm’s 50-day simple moving average is $0.87 and its 200 day simple moving average is $1.07.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.24. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $2.50 million. Regulus Therapeutics had a negative net margin of 396.84% and a negative return on equity of 186,717.70%. Sell-side analysts expect that Regulus Therapeutics Inc will post -2.04 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of RGLS. Virtu Financial LLC bought a new stake in Regulus Therapeutics during the first quarter worth $68,000. Wedbush Securities Inc. raised its position in Regulus Therapeutics by 32.8% during the first quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,751 shares in the last quarter. NEA Management Company LLC raised its position in Regulus Therapeutics by 124.1% during the second quarter. NEA Management Company LLC now owns 2,052,455 shares of the biopharmaceutical company’s stock worth $2,566,000 after acquiring an additional 1,136,704 shares in the last quarter. Samsara BioCapital LLC bought a new stake in Regulus Therapeutics during the second quarter worth $1,131,000. Finally, EcoR1 Capital LLC bought a new stake in Regulus Therapeutics during the second quarter worth $1,389,000. Institutional investors and hedge funds own 18.15% of the company’s stock.

About Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Read More: Cryptocurrencies

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.